• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种用于快速定量人血浆中抗逆转录病毒药物达匹韦林的超高效液相色谱-串联质谱法的开发与验证。

The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma.

作者信息

Seserko Lauren A, Emory Joshua F, Hendrix Craig W, Marzinke Mark A

机构信息

Division of Clinical Pharmacology, Department of Medicine, The Johns Hopkins University School of Medicine, 600 North Wolfe St, Osler 501, Baltimore, MD 21287, USA.

出版信息

Bioanalysis. 2013 Nov;5(22):2771-83. doi: 10.4155/bio.13.256.

DOI:10.4155/bio.13.256
PMID:24256358
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4104354/
Abstract

BACKGROUND

Dapivirine is a non-nucleoside reverse transcriptase inhibitor designed to prevent HIV-1 viral replication and subsequent propagation. A sensitive method is required to quantify plasma concentrations to assess drug efficacy.

RESULTS

Dapivirine-spiked plasma was combined with acetonitrile containing deuterated IS and was processed for analysis. The method has an analytical measuring range from 20 to 10,000 pg/ml. For the LLOQ, low, mid and high QCs, intra- and inter-assay precision (%CV) ranged from 5.58 to 13.89% and 5.23 to 13.36%, respectively, and intra- and inter-day accuracy (% deviation) ranged from -5.61 to 0.75% and -4.30 to 6.24%, respectively.

CONCLUSION

A robust and sensitive LC-MS/MS assay for the high-throughput quantification of the antiretroviral drug dapivirine in human plasma was developed and validated following bioanalytical validation guidelines. The assay meets criteria for the analysis of samples from large research trials.

摘要

背景

达匹韦林是一种非核苷类逆转录酶抑制剂,旨在防止HIV-1病毒复制及后续传播。需要一种灵敏的方法来定量血浆浓度以评估药物疗效。

结果

将添加了达匹韦林的血浆与含有氘代内标的乙腈混合,并进行分析处理。该方法的分析测量范围为20至10,000 pg/ml。对于最低定量限、低、中、高质控样品,批内和批间精密度(%CV)分别为5.58%至13.89%和5.23%至13.36%,批内和日间准确度(%偏差)分别为-5.61%至0.75%和-4.30%至6.24%。

结论

按照生物分析验证指南,开发并验证了一种用于高通量定量人血浆中抗逆转录病毒药物达匹韦林的稳健且灵敏的液相色谱-串联质谱法。该方法符合大型研究试验样品分析的标准。

相似文献

1
The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma.一种用于快速定量人血浆中抗逆转录病毒药物达匹韦林的超高效液相色谱-串联质谱法的开发与验证。
Bioanalysis. 2013 Nov;5(22):2771-83. doi: 10.4155/bio.13.256.
2
Validation and implementation of an ultrasensitive liquid chromatographic-tandem mass spectrometric (LC-MS/MS) assay for dapivirine quantitation in breast milk.一种用于母乳中地匹韦林定量分析的超灵敏液相色谱-串联质谱(LC-MS/MS)检测方法的验证与应用。
Clin Biochem. 2020 Aug;82:66-72. doi: 10.1016/j.clinbiochem.2019.12.005. Epub 2019 Dec 13.
3
Dual quantification of dapivirine and maraviroc in cervicovaginal secretions from ophthalmic tear strips and polyester-based swabs via liquid chromatographic-tandem mass spectrometric (LC-MS/MS) analysis.通过液相色谱-串联质谱(LC-MS/MS)分析对来自眼科泪液试纸和聚酯拭子的宫颈阴道分泌物中的达匹韦林和马拉维若进行双重定量。
J Pharm Biomed Anal. 2014 Sep;98:407-16. doi: 10.1016/j.jpba.2014.06.018. Epub 2014 Jun 21.
4
Development and validation of an UHPLC-MS/MS method for simultaneous quantification of ibrutinib and its dihydrodiol-metabolite in human cerebrospinal fluid.建立并验证 UHPLC-MS/MS 法同时测定人脑脊液中伊布替尼及其二氢二醇代谢物的浓度
J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Sep 1;1093-1094:158-166. doi: 10.1016/j.jchromb.2018.06.026. Epub 2018 Jun 15.
5
Validation of an electrospray ionization LC-MS/MS method for quantitative analysis of raltegravir, etravirine, and 9 other antiretroviral agents in human plasma samples.验证一种电喷雾电离 LC-MS/MS 方法,用于定量分析人血浆样品中的拉替拉韦、依曲韦林和其他 9 种抗逆转录病毒药物。
Ther Drug Monit. 2009 Dec;31(6):695-702. doi: 10.1097/FTD.0b013e3181c05adf.
6
Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.用于定量测定人血浆中CCR5拮抗剂马拉维若的液相色谱-串联质谱(LC-MS/MS)方法的开发与生物分析验证。
Clin Chim Acta. 2014 Apr 20;431:198-205. doi: 10.1016/j.cca.2014.02.008. Epub 2014 Feb 19.
7
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.用于在人血浆和组织中多重定量测定依曲韦林、马拉维若、拉替拉韦和利匹韦林的液相色谱-串联质谱法的开发与验证
J Pharm Biomed Anal. 2016 Nov 30;131:333-344. doi: 10.1016/j.jpba.2016.08.016. Epub 2016 Sep 4.
8
A sensitive and selective liquid chromatography/tandem mass spectrometry method for quantitative analysis of efavirenz in human plasma.一种灵敏且选择性的液相色谱/串联质谱法,用于人血浆中依非韦伦的定量分析。
PLoS One. 2013 Jun 5;8(6):e63305. doi: 10.1371/journal.pone.0063305. Print 2013.
9
Validation and implementation of liquid chromatographic-mass spectrometric (LC-MS) methods for the quantification of tenofovir prodrugs.验证和实施液相色谱-质谱(LC-MS)方法,用于定量测定替诺福韦前药。
J Pharm Biomed Anal. 2018 Apr 15;152:248-256. doi: 10.1016/j.jpba.2018.02.011. Epub 2018 Feb 8.
10
A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.一种灵敏的 HPLC-MS/MS 法测定人血浆中的多替拉韦。
J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Jan 15;945-946:225-32. doi: 10.1016/j.jchromb.2013.11.054. Epub 2013 Dec 3.

引用本文的文献

1
Safety and drug quantification of the dapivirine vaginal ring and oral pre-exposure prophylaxis in breastfeeding mother-infant pairs (MTN-043): a phase 3B, open-label, randomised trial.达匹韦林阴道环与口服暴露前预防在母乳喂养母婴对中的安全性及药物定量研究(MTN-043):一项3B期、开放标签、随机试验
Lancet HIV. 2025 Mar;12(3):e180-e190. doi: 10.1016/S2352-3018(24)00306-0. Epub 2025 Feb 12.
2
Rapid and sensitive liquid chromatographic-tandem mass spectrometric methods for the quantitation of dolutegravir in human plasma and breast milk.用于定量测定人血浆和母乳中多替拉韦的快速灵敏液相色谱-串联质谱法。
J Mass Spectrom Adv Clin Lab. 2024 Sep 19;34:1-7. doi: 10.1016/j.jmsacl.2024.09.001. eCollection 2024 Nov.
3
Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings.评估延长使用度吡非尼酮和左炔诺孕酮阴道环的安全性、药代动力学和与阴道出血相关的 1 期随机试验。
PLoS One. 2024 Jun 5;19(6):e0304552. doi: 10.1371/journal.pone.0304552. eCollection 2024.
4
Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.评估使用地蒽酚阴道环降低女性每次性行为中 HIV-1 风险的效果。
J Infect Dis. 2024 Apr 12;229(4):1158-1165. doi: 10.1093/infdis/jiad550.
5
MTN-033: a Phase 1 Study Comparing Applicator versus "as Lubricant" Delivery of Rectal Dapivirine Gel.MTN-033:比较直肠双呋喹地尔凝胶经给药器给药与“作为润滑剂”给药的 1 期研究。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0081622. doi: 10.1128/aac.00816-22. Epub 2022 Oct 18.
6
A Randomized, Double Blind, Placebo-Controlled, Phase 1 Safety, and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults (MTN-026).一项随机、双盲、安慰剂对照、Ⅰ期安全性和药代动力学研究:直肠给予 HIV-1 血清阴性成人(MTN-026)双夫定凝胶(0.05%)。
AIDS Res Hum Retroviruses. 2022 Apr;38(4):257-268. doi: 10.1089/AID.2021.0071. Epub 2021 Dec 6.
7
Phase 1 pharmacokinetics and safety study of extended duration dapivirine vaginal rings in the United States.美国多替拉韦阴道环延长释放时间的 1 期药代动力学和安全性研究。
J Int AIDS Soc. 2021 Jun;24(6):e25747. doi: 10.1002/jia2.25747.
8
Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.抗 HIV-1 感染的双夫定阴道环的依从性相关因素。
AIDS Behav. 2021 Sep;25(9):2801-2814. doi: 10.1007/s10461-021-03231-x. Epub 2021 Jun 11.
9
Tandem mass spectrometry of small-molecule antiviral drugs: 1. HIV-related antivirals.小分子抗病毒药物的串联质谱分析:1. 与HIV相关的抗病毒药物。
Int J Mass Spectrom. 2020 Sep;455:116370. doi: 10.1016/j.ijms.2020.116370. Epub 2020 Jun 15.
10
Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.从 dapivirine 阴道环中释放出更多的 dapivirine 与降低 HIV-1 感染风险相关:一项随机、安慰剂对照试验的二次分析。
J Int AIDS Soc. 2020 Nov;23(11):e25634. doi: 10.1002/jia2.25634.

本文引用的文献

1
A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action.一种用于预防艾滋病病毒的含两种作用机制不同的杀菌剂的硅橡胶阴道环。
Eur J Pharm Sci. 2013 Feb 14;48(3):406-15. doi: 10.1016/j.ejps.2012.12.002. Epub 2012 Dec 21.
2
Development and validation of a HPLC method for the assay of dapivirine in cell-based and tissue permeability experiments.建立并验证一种 HPLC 方法,用于检测细胞试验和组织渗透实验中的地匹福林含量。
J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 12;911:76-83. doi: 10.1016/j.jchromb.2012.10.034. Epub 2012 Nov 2.
3
Vaginal rings for delivery of HIV microbicides.阴道环用于递送 HIV 杀微生物剂。
Int J Womens Health. 2012;4:595-605. doi: 10.2147/IJWH.S36282. Epub 2012 Nov 20.
4
Preexposure prophylaxis for HIV infection among African women.预防非洲女性感染 HIV 的暴露前预防措施。
N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.
5
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.博茨瓦纳异性传播 HIV 中抗逆转录病毒的预先暴露预防。
N Engl J Med. 2012 Aug 2;367(5):423-34. doi: 10.1056/NEJMoa1110711. Epub 2012 Jul 11.
6
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.抗逆转录病毒预防治疗用于异性恋男性和女性的 HIV 预防。
N Engl J Med. 2012 Aug 2;367(5):399-410. doi: 10.1056/NEJMoa1108524. Epub 2012 Jul 11.
7
Development and Characterization of a Vaginal Film Containing Dapivirine, a Non- nucleoside Reverse Transcriptase Inhibitor (NNRTI), for prevention of HIV-1 sexual transmission.一种含达匹韦林(一种非核苷类逆转录酶抑制剂(NNRTI))的阴道膜用于预防HIV-1性传播的研发与特性研究
Drug Deliv Transl Res. 2011 Jun 1;1(3):209-222. doi: 10.1007/s13346-011-0022-6.
8
Antiviral agents and HIV prevention: controversies, conflicts, and consensus.抗病毒药物和艾滋病预防:争议、冲突与共识。
AIDS. 2012 Aug 24;26(13):1585-98. doi: 10.1097/QAD.0b013e3283543e83.
9
Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.联合应用杀微生物剂抗逆转录病毒药物地匹福韦和替诺福韦,抗击耐药性 HIV-1。
AIDS. 2011 Aug 24;25(13):1585-94. doi: 10.1097/QAD.0b013e3283491f89.
10
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.男男性行为人群 HIV 预防的暴露前药物预防。
N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.